Lead Product(s) : Debio 0123,Sacituzumab Govitecan
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : MEDSIR
Deal Size : Inapplicable
Deal Type : Inapplicable
MEDSIR & Debiopharm Begin WIN-B Trial in Breast Cancer
Details : Debio 0123 is an oral, potent, highly selective, and brain-penetrant WEE1 inhibitor is being evaluated with trodelvy for HR-positive/HER2-negative triple negative breast neoplasms.
Product Name : Debio 0123
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 25, 2025
Lead Product(s) : Debio 0123,Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : MEDSIR
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Debio 0123
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Debiopharm Expands WEE1 Inhibitor Research in Gynecological and Biomarker-Driven Tumors
Details : Debio 0123, an oral, potent, highly selective, and brain-penetrant WEE1 inhibitor is being evaluated in Phase I clinical trial studies for patients with advanced solid tumors.
Product Name : Debio 0123
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 03, 2024
Lead Product(s) : Debio 0123
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Debio 0123,Sacituzumab Govitecan
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Collaboration
MEDSIR & Debiopharm Explore Synergy of Debio 0123 & Sacituzumab in Breast Cancer
Details : The collaboration aims to evaluate the safety and efficacy of Debio 0123, Debiopharm's investigational, potential best-in-class WEE1 inhibitor, together with Trodelvy (sacituzumab govitecan).
Product Name : Debio 0123
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 28, 2024
Lead Product(s) : Debio 0123,Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Lunresertib,Debio 0123
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Debiopharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Repare and Debiopharm Dosed First Patient in Phase 1/1b MYTHIC Trial
Details :
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 30, 2024
Lead Product(s) : Lunresertib,Debio 0123
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Debiopharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Debio 0123,Lunresertib
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Collaboration
Debiopharm Partners with Repare To Explore PKMYT1 and WEE1 Inhibition
Details :
Product Name : Debio 0123
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 01, 2024
Lead Product(s) : Debio 0123,Lunresertib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Debio 0123,Carboplatin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Debio 0123 is a brain-penetrant, highly selective WEE1 kinase inhibitor combines with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC).
Product Name : Debio 0123
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2023
Lead Product(s) : Debio 0123,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Debio 0123,Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Debio 0123 is a brain-penetrant and highly selective WEE1 inhibitor, it is being investigated in combination with temozolomide (TMZ) in patients with recurrent or progressive glioblastoma and in combination with TMZ/RT (SOC) in newly diagnosed patients.
Product Name : Debio 0123
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2023
Lead Product(s) : Debio 0123,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Debio 0123
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dose escalation, monotherapy trial launched to access the safety and preliminary anti-tumor activity of Debio 0123 in the treatment of advanced solid tumors.
Product Name : Debio 0123
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2021
Lead Product(s) : Debio 0123
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Debio 0123
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor
Details : Debio 0123 starts first-in-human, dose escalation phase I clinical trial assessing the safety and efficacy of the compound in combination with carboplatin to treat refractory solid tumors.
Product Name : Debio 0123
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 03, 2020
Lead Product(s) : Debio 0123
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable